KalVista Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KALV research report →
Range $27 – $32
Price Chart
About the company
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa.
- CEO
- Benjamin L. Palleiko
- IPO
- 2015
- Employees
- 275
- HQ
- Framingham, MA, US
Get TickerSpark's AI analysis on KALV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.44B
- P/E
- -8.36
- Fwd P/E
- 42.19
- PEG
- -0.56
- P/S
- 12.40
- P/B
- -503.31
- EV/EBITDA
- -12.72
- Div Yield
- 0.00%
- Gross Margin
- 92.03%
- Op Margin
- -120.80%
- Net Margin
- -119.44%
- ROE
- -1057.44%
- ROIC
- -46.81%
Latest fiscal year · YoY change
- Revenue
- $73.62M+0.0%
- Gross Profit
- $67.54M+0.0%
- Op Income
- $-171,838,500
- Net Income
- $-164,286,000+10.4%
- EPS
- $-3.23+12.5%
- OCF Growth
- +46.6%
- FCF Growth
- +45.7%
- 52W High
- $27.00
- 52W Low
- $9.83
- 50D MA
- $24.43
- 200D MA
- $17.09
- Beta
- -0.29
- RSI (14)
- 76
- Avg Volume
- 3.63M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
KalVista’s first commercial quarter for EKTERLY showed a strong U.S. launch, early payer progress, and enough cash to fund operations into 2027.· September 11, 2025
- FDA approved EKTERLY on July 7 as the first and only oral on-demand therapy for acute HAE attacks in adults and patients ages 12+.
- Initial U.S. launch metrics were strong: 460 patient start forms in the 8 weeks ending August 29, more than 4,000 people joined the patient database, and 253 unique prescribers were activated.
- The company reported $1.4 million in net revenue for the launch period, with total operating expenses of $60.4 million.
- Management said all 460 start forms also received Quickstart, and some paid shipments and first refills have already begun.
- Cash and investments were about $191 million at July 31, and management expects that plus forecasted EKTERLY revenue to fund operations into 2027.
KalVista reported first sale of EKTERLY and $1.4 million in net revenue for the launch period, primarily from stocking orders by specialty pharmacies and the commercial distribution network. Total operating expenses were $60.4 million, including about $15 million in R&D and about $45 million in SG&A; the SG&A increase was driven mainly by external spending for the EKTERLY launch. Cash and investments were approximately $191 million at July 31, 2025, and management said that balance plus forecasted EKTERLY revenue should fund operations into 2027. For the U.S. launch, the company reported 460 patient start forms in the 8-week period ending August 29, more than 4,000 people in the patient database, 253 unique prescribers activated, and over 72% of the physician base reached, including 96% of Tier 1 physicians. Management did not provide full-year revenue or EPS guidance on the call.
Ben Palleiko framed the quarter as a landmark moment, emphasizing that FDA approval made EKTERLY the first oral on-demand option for acute HAE attacks and saying the launch response had exceeded expectations. He stressed that almost 5% of the U.S. HAE population had already submitted a prescription and that the early demand was broad across patients, physicians, and payers. His tone was upbeat and confident, with repeated comments that EKTERLY could become the foundational HAE treatment globally and redefine standard of care.
Brian Piekos highlighted the first $1.4 million in net revenue, which he said mainly came from stocking orders, and total operating expenses of $60.4 million split between roughly $15 million of R&D and $45 million of SG&A. He said SG&A rose mainly because of launch-related external spending, and he expects operating expenses to stay relatively consistent for the rest of 2025 as the company continues investing in the launch. He also said the company had about $191 million in cash and investments at July 31 and that this, together with forecasted EKTERLY revenue, should fund operations into 2027.
Analysts focused on the mechanics of Quickstart, the timing of paid reimbursement, and how start forms would translate into paid prescriptions and refills. Management explained that all 460 start forms also received Quickstart at no charge while the company works through medical exceptions and payer access, and said some paid shipments and first refills have already started to appear. Questions also covered launch metrics, with management saying KPIs will evolve toward repeat prescribing, refills, and utilization per patient, and that more access-related disclosure may come later. On access hurdles, management said only one step-through generic icatibant instance had been seen and that most patients can move through that process quickly because many already have icatibant experience.
The call showed an unusually strong early commercial start, with management saying demand was higher than expected, growing steadily, and broad across prior therapies and prophylaxis backgrounds. Management also pointed to early paid access, first refills, strong physician reach, and positive patient feedback, suggesting the launch is moving beyond mere awareness into actual utilization. Cash appears sufficient to support the buildout while the company pursues ex-U.S. approvals and launches.
The launch is still very early, and management acknowledged that formal coverage policies can take up to six months to establish, so the conversion from Quickstart to paid drug remains a key execution risk. Revenue is still small at $1.4 million, while operating expenses were $60.4 million, so the company remains heavily dependent on launch traction and future reimbursement. Management also flagged that KPIs will change over time, which means near-term visibility into true consumption and repeat use is still limited.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 71.7%
- Shares Outstanding
- 53.24M
- Float Shares
- 38.18M
of shares held by institutions
165 13F filers
Buy/sell ratio 0.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for KALV, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Chris JacobsHouse · NY27 | Buy | Dec 12, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.51M | ▲ 7.90K |
| Tudor Investment Corp Et Al | 2.00M | ▲ 2.00M |
| Alphaquest LLC | 52.19K | ▲ 415 |
| Allostery Investments LP | 40.00K | ▼ 418.30K |
| Hap Trading, LLC | 31.22K | ▲ 31.22K |
| Sherbrooke Park Advisers LLC | 11.42K | ▼ 4.25K |
| Janus Henderson Group Ltd. | 10.90K | 0 |
| Martin Worley Group | 10.17K | 0 |
| Cwm, LLC | 901 | ▲ 242 |
| Comerica Bank | 519 | 0 |
| Parkworth Wealth Management, Inc. | 22 | ▲ 22 |
| Sunbelt Securities, Inc. | 9 | 0 |
Held by 10 ETFs
Biggest fund positions in KALV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | Stuart Nancy | sell | 14,000 |
| Jun 11, 26 | Stuart Nancy | sell | 10,000 |
| Jun 11, 26 | Stuart Nancy | sell | 10,000 |
| Jun 11, 26 | Stuart Nancy | sell | 10,000 |
| Jun 11, 26 | Stuart Nancy | sell | 30,000 |
| Jun 11, 26 | Pereira Brian JG | sell | 14,000 |
| Jun 11, 26 | Pereira Brian JG | sell | 7,000 |
| Jun 11, 26 | Pereira Brian JG | sell | 10,000 |
| Jun 11, 26 | Pereira Brian JG | sell | 10,000 |
| Jun 11, 26 | Pereira Brian JG | sell | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KALV coverage
Recent articles, reports, and earnings notes.
No research on KALV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KALV report →Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
businesswire.com · Jun 11
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Jun 4
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
fool.com · May 31
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
gurufocus.com · May 28
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
businesswire.com · May 28
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
gurufocus.com · May 19
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
businesswire.com · May 19
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
businesswire.com · May 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.